Talk:5-HT2 receptor

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Untitled

How can agomelatine be listed as both an agonist and an antagonist?

That must be an error? I am not a biochemist but one reference (M. J. Millan, A. Gobert, F. Lejeune, A. Dekeyne, A. Newman-Tancredi, V. Pasteau, J.-M. Rivet & D. Cussac (2003). "The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways". The Journal of pharmacology and experimental therapeutics. 306 (3): 954–954. doi:10.1124/jpet.103.051797. PMID 12750432. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)) calls it a melatonin agonist and a 2C antagonist, so I have erased agomelatine from the list of agonists. — fnielsen (talk) 10:02, 9 October 2008 (UTC)[reply]